Aurora Rejects Curaleaf's Revised Hostile Bid, Reveals Active Strategic Alternatives Process
ACB sits 63% above its 52-week low of $2.56.
Summary
Aurora Cannabis reaffirms its rejection of Curaleaf's revised hostile bid and discloses an active strategic alternatives process with multiple third parties under confidentiality agreements.
Key Events · M&A and Partnerships · ACB
-
Revised Hostile Bid Rejected
Aurora's board unanimously recommends shareholders reject Curaleaf's revised hostile bid, filed October 6, 2026, citing an updated inadequacy opinion from its financial advisor.
-
Strategic Alternatives Process Active
Aurora's Special Committee has entered into confidentiality and standstill agreements with multiple third parties and is exploring a possible transaction or remaining independent.
-
Bid Open Until December 4, 2026
Curaleaf's revised offer remains open until December 4, 2026, giving Aurora time to surface superior alternatives before shareholders must decide.
-
Board Cites Undervaluation and Risk
Aurora argues the revised bid uses Aurora's own cash to fund the acquisition, relies on inflated Curaleaf shares, and fails to reflect Aurora's debt-free balance sheet and global earnings power.
Analysis · ACB · Life Sciences
The battle for Aurora Cannabis has escalated, with this filing revealing a revised hostile bid from Curaleaf and a board that remains firmly opposed. On October 6, 2026, Curaleaf amended its offer, but Aurora's directors unanimously recommend rejection, supported by an updated fairness opinion that deems the consideration inadequate. More significantly, Aurora discloses that it has signed confidentiality and standstill agreements with multiple third parties and is actively exploring strategic alternatives—including a possible sale to another buyer or remaining independent. This suggests a competitive auction process may be underway, potentially driving a higher price for shareholders. With the bid open until December 4, 2026, Aurora has time to surface a superior offer.
How filings like this one have moved
In the 30 days to Oct 29, 2026, 38.8% of the 970 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.46%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ACB was trading at $4.17 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $270.4M. The 52-week trading range was $2.56 to $6.36. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.